We use cookies for a better user experience. Read our Privacy Policy

I Agree

Thrombosis Drugs Market

Thrombosis Drugs Market (Drug Class - Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor; Indication - Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Thrombosis Drugs Market – An Overview

Over the forecast period of 2018 to 2026, notable growth would be charted by global thrombosis drugs market, creating a string of advantageous opportunities and driving the market valuation to a higher worth. Multiple factors of growth are helping the global thrombosis drugs market stay on an upward and steep growth curve over the stated period. Some of these include poor lifestyle choices gaining foothold among consumers, increasing burden of cardiovascular diseases, and growing government efforts towards improvement in healthcare outcomes.

A detailed overview of trends and drivers that are contributing significantly to growth in the global thrombosis drugs market can be found below:

  •  Number of people in the geriatric age group is increasing and it is increasing at a rapid pace. As per research undertaken recently, there would be an increase from approximately 970million in 2017 to 2 billion in 2050 in the number of people aged 60 and above. This phenomenon is going to be quite pronounced in regions of Europe and North America where one in every four people will be aged 65 and above by this year. One in every six people will be the ratio of people in this age group across the world. This demographic is a major consumer of thrombosis drugs and is therefore set to propel notable growth in the market.
  • Research and development in the market is witnessing increase in activity and intensity – a result of growing number of cases of cardiovascular diseases. Poor diet and habits such as excessive drinking and smoking is leading to increase in incidence of these diseases across the globe. This is contributing massively to growth that is anticipated in the global thrombosis drugs market. Additionally, obesity or being over-weight is also increasing the risk of CVD, driving demand for thrombosis drugs by a notable factor over the forecast period,

Global Thrombosis Drugs Market - Snapshot

Thrombosis is the medical term for an abnormal blood clot in an artery or vein. Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. Medication to treat is likely to include anticoagulants drugs and thrombin inhibitors drugs. In terms of revenue, the global thrombosis market was valued at approximately US$ 20,000 Mn in 2017 and is anticipated to surpass US$ 47,000 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2026. Rise in the number of patients affected by thrombosis and availability of new drugs formulation products with improved features are likely to fuel the global thrombosis drugs market from 2018 to 2026.

Thrombosis drugs are generally blood thinners. These drugs decrease the clotting power of blood and consequently, the chances of thrombosis events, such as pulmonary embolism, decrease. These drugs are available in the form of injection, capsule, and tablet. Key players are focusing on the development of drugs with better efficacy. For instance, Grifols Therapeutics Inc., a U.S.-based biotechnology company is projected to launch AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass. Such key developments are likely to fuel the global thrombosis drugs market in the near future. However, the high price of non-vitamin K oral anticoagulant drugs and the availability of generic drugs are likely to hamper the global thrombosis drugs market during the forecast period.

thrombosis-drugs-market.jpg

Several unmet needs are anticipated to create significant opportunities for existing players and new entrants in the global thrombosis drugs market. Rapid technological advancements in treatment therapies create opportunities for players operating in the global thrombosis drugs market. Ongoing developments in thrombosis drugs, such as Revo Biologic’s ATryn with continuous infusion of drugs are likely drive the thrombosis drugs market during the forecast period.

The global thrombosis drugs market can be segmented based on drug class, indication, distribution channel, and geography. In terms of drug class, the factor Xa inhibitor segment dominated the market and is expected to continue this trend during the forecast period, followed by the P2Y12 platelet inhibitor segment. Increasing preference for the usage of oral anticoagulant drugs with predictable dose release response is likely to propel the segment during the forecast period. The low molecular weight heparin drug class segment, is likely to lose market share during the forecast period owing to patent expiry. Based on indication, the pulmonary embolism segment led the market, in terms of revenue, in 2017. The segment is projected to continue to dominate the market during the forecast period. In terms of distribution channel, the hospital pharmacies segment accounted for a large share of the market in 2017 and is likely to continue its dominance during the forecast period.

In terms of geography, North America held a major share of the global thrombosis drugs market in 2017. High utilization rate of new oral anticoagulant drugs is a key factor that propels the market in North America. Moreover, favorable reimbursement for the treatment of different thrombosis events under Medicare policy also boosts the market in this region. In terms of revenue, the market in Europe and Asia Pacific is projected to expand during the forecast period. Rising prevalence of deep vein thrombosis and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa.

Key companies operating in the global thrombosis drugs market, which are profiled in the report, include GlaxoSmithKline plc., Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share. For instance, in September 2014, Mylan Inc., acquired the U.S. commercialization, marketing, and intellectual property rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic of Arixtra from Aspen Global Incorporated. This acquisition enhanced Mylan Inc’s expansion opportunities in the U.S. market.

The global thrombosis drugs market has been segmented as follows:

Drug Class

  • Factor Xa Inhibitor
  • Low Molecular Weight Heparin
  • P2Y12 Platelet Inhibitor
  • Others

Indication

  • Pulmonary Embolism
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Thrombosis Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary : Global Thrombosis Drugs Market

Chapter 4. Market Overview
4.1. Introduction
       4.1.1. Drug Class Overview
4.2. Market Dynamics
       4.2.1. Drivers
       4.2.2. Restraints
       4.2.3. Opportunities
4.3. Pipeline Analysis – Thrombosis Drugs Market
4.4. Thrombosis Drugs Sales Analysis
4.5. Thrombosis Drugs Market Value Chain Analysis
4.6. Global Thrombosis Drugs Market Analysis and Forecasts, 2016–2026
       4.6.1. Market Revenue Projection (US$ Mn)
       4.6.2. Market Outlook
4.7. Key Trends

Chapter 5. Global Thrombosis Drugs Market Analysis and Forecasts, by Drug Class
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drug Class, 2017–2026
       5.3.1. Factor Xa Inhibitor
       5.3.2. Low Molecular Weight Heparin
       5.3.3. P2Y12 Platelet Inhibitor
       5.3.4. Others
5.4. Market Attractiveness, by Drug Class

Chapter 6. Global Thrombosis Drugs Market Analysis and Forecasts, by Indication
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Indication, 2017–2026
       6.3.1. Pulmonary Embolism
       6.3.2. Atrial Fibrillation
       6.3.3. Deep Vein Thrombosis
       6.3.4. Others
6.4. Market Attractiveness, by Indication

Chapter 7. Global Thrombosis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Distribution Channel, 2017–2026
       7.3.1. Hospital Pharmacies
       7.3.2. Retail Pharmacies
       7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel

Chapter 8. Global Thrombosis Drugs Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
       8.2.1. North America
       8.2.2. Europe
       8.2.3. Asia Pacific
       8.2.4. Latin America
       8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Thrombosis Drugs Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017–2026
       9.1.1. U.S.
       9.1.2. Canada
9.2. Market Value Share Analysis, by Drug Class, 2017–2026
9.3. Market Value Forecast, by Drug Class, 2016–2026
       9.3.1. Factor Xa Inhibitor
       9.3.2. Low Molecular Weight Heparin
       9.3.3. P2Y12 Platelet Inhibitor
       9.3.4. Others
9.4. Market Value Share Analysis, by Indication, 2017–2026
9.5. Market Value Forecast, by Indication, 2016–2026
       9.5.1. Pulmonary Embolism
       9.5.2. Atrial Fibrillation
       9.5.3. Deep Vein Thrombosis
       9.5.4. Others
9.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
9.7. Market Value Forecast, by Distribution Channel, 2016–2026
       9.7.1. Hospital Pharmacies
       9.7.2. Retail Pharmacies
       9.7.3. Online Pharmacies
9.8. Market Attractiveness Analysis
       9.8.1. By Country
       9.8.2. By Drug Class
       9.8.3. By Indication
       9.8.4. By Distribution Channel

Chapter 10. Europe Thrombosis Drugs Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2017–2025
       10.1.1. Germany
       10.1.2. France
       10.1.3. U.K.
       10.1.4. Spain
       10.1.5. Italy
       10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Drug Class, 2017–2026
10.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
       10.3.1. Factor Xa Inhibitor
       10.3.2. Low Molecular Weight Heparin
       10.3.3. P2Y12 Platelet Inhibitor
       10.3.4. Others
10.4. Market Value Share Analysis, by Indication, 2017–2026
10.5. Market Value Forecast, by Indication, 2016–2026
       10.5.1. Pulmonary Embolism
       10.5.2. Atrial Fibrillation
       10.5.3. Deep Vein Thrombosis
       10.5.4. Others
10.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
10.7. Market Value Forecast, by Distribution Channel, 2016–2026
       10.7.1. Hospital Pharmacies
       10.7.2. Retail Pharmacies
       10.7.3. Online Pharmacies
10.8. Market Attractiveness Analysis
       10.8.1. By Country
       10.8.2. By Drug Class
       10.8.3. By Indication
       10.8.4. By Distribution Channel

Chapter 11. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2017–2025
       11.1.1. China
       11.1.2. Japan
       11.1.3. India
       11.1.4. Australia & New Zealand
       11.1.5. Rest of APAC
11.2. Market Value Share Analysis, by Drug Class, 2017–2026
11.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
       11.3.1. Factor Xa Inhibitor
       11.3.2. Low Molecular Weight Heparin
       11.3.3. P2Y12 Platelet Inhibitor
       11.3.4. Others
11.4. Market Value Share Analysis, by Indication, 2017–2026
11.5. Market Value Forecast, by Indication, 2016–2026
       11.5.1. Pulmonary Embolism
       11.5.2. Atrial Fibrillation
       11.5.3. Deep Vein Thrombosis
       11.5.4. Others
11.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
11.7. Market Value Forecast, by Distribution Channel, 2016–2026
       11.7.1. Hospital Pharmacies
       11.7.2. Retail Pharmacies
       11.7.3. Online Pharmacies
11.8. Market Attractiveness Analysis
       11.8.1. By Country
       11.8.2. By Drug Class
       11.8.3. By Indication
       11.8.4. By Distribution Channel

Chapter 12. Latin America Thrombosis Drugs Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2017–2025
       12.1.1. Brazil
       12.1.2. Mexico
       12.1.3. Rest of LATAM
12.2. Market Value Share Analysis, by Drug Class, 2017–2026
12.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
       12.3.1. Factor Xa Inhibitor
       12.3.2. Low Molecular Weight Heparin
       12.3.3. P2Y12 Platelet Inhibitor
       12.3.4. Others
12.4. Market Value Share Analysis, by Indication, 2017–2026
12.5. Market Value Forecast, by Indication, 2016–2026
       12.5.1. Pulmonary Embolism
       12.5.2. Atrial Fibrillation
       12.5.3. Deep Vein Thrombosis
       12.5.4. Others
12.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
12.7. Market Value Forecast, by Distribution Channel, 2016–2026
       12.7.1. Hospital Pharmacies
       12.7.2. Retail Pharmacies
       12.7.3. Online Pharmacies
12.8. Market Attractiveness Analysis
       12.8.1. By Country
       12.8.2. By Drug Class
       12.8.3. By Indication
       12.8.4. By Distribution Channel

Chapter 13. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2017–2025
       13.1.1. GCC Countries
       13.1.2. South Africa
       13.1.3. Israel
       13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Drug Class, 2017–2026
13.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
       13.3.1. Factor Xa Inhibitor
       13.3.2. Low Molecular Weight Heparin
       13.3.3. P2Y12 Platelet Inhibitor
       13.3.4. Others
13.4. Market Value Share Analysis, by Indication, 2017–2026
13.5. Market Value Forecast, by Indication, 2016–2026
       13.5.1. Pulmonary Embolism
       13.5.2. Atrial Fibrillation
       13.5.3. Deep Vein Thrombosis
       13.5.4. Others
13.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
13.7. Market Value Forecast, by Distribution Channel, 2016–2026
       13.7.1. Hospital Pharmacies
       13.7.2. Retail Pharmacies
       13.7.3. Online Pharmacies
13.8. Market Attractiveness Analysis
       13.8.1. By Country
       13.8.2. By Drug Class
       13.8.3. By Indication
       13.8.4. By Distribution Channel

Chapter 14. Competition Landscape
14.1. Competition Matrix
       14.1.1. GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd.
       14.1.2. Baxter International, Inc.
14.2. Company Profiles
       14.2.1. GlaxoSmithKline plc.
                14.2.1.1. Company Details
                14.2.1.2. Company Description
                14.2.1.3. Business Overview
                14.2.1.4. SWOT Analysis
                14.2.1.5. Financial Analysis
                14.2.1.6. Strategic Overview
       14.2.2. Baxter International, Inc.
                14.2.2.1. Company Details
                14.2.2.2. Company Description
                14.2.2.3. Business Overview
                14.2.2.4. SWOT Analysis
                14.2.2.5. Strategic Overview
       14.2.3. Johnson & Johnson
                14.2.3.1. Company Details
                14.2.3.2. Company Description
                14.2.3.3. Business Overview
                14.2.3.4. SWOT Analysis
                14.2.3.5. Strategic Overview
       14.2.4. Bayer AG
                14.2.4.1. Company Details
                14.2.4.2. Company Description
                14.2.4.3. Business Overview
                14.2.4.4. SWOT Analysis
                14.2.4.5. Strategic Overview
       14.2.5. Sanofi
                14.2.5.1. Company Details
                14.2.5.2. Company Description
                14.2.5.3. Business Overview
                14.2.5.4. SWOT Analysis
                14.2.5.5. Financial Analysis
                14.2.5.6. Strategic Overview
       14.2.6. Bristol-Myers Squibb Company
                14.2.6.1. Company Details
                14.2.6.2. Company Description
                14.2.6.3. Business Overview
                14.2.6.4. SWOT Analysis
                14.2.6.5. Financial Analysis
                14.2.6.6. Strategic Overview
       14.2.7. AstraZeneca plc
                14.2.7.1. Company Details
                14.2.7.2. Company Description
                14.2.7.3. Business Overview
                14.2.7.4. SWOT Analysis
                14.2.7.5. Financial Analysis
                14.2.7.6. Strategic Overview
       14.2.8. Pfizer, Inc.
                14.2.8.1. Company Details
                14.2.8.2. Company Description
                14.2.8.3. Business Overview
                14.2.8.4. SWOT Analysis
                14.2.8.5. Financial Analysis
                14.2.8.6. Strategic Overview
       14.2.9. Boehringer Ingelheim GmbH
                14.2.9.1. Company Details
                14.2.9.2. Company Description
                14.2.9.3. Business Overview
                14.2.9.4. SWOT Analysis
                14.2.9.5. Strategic Overview
       14.2.10. Aspen Pharmacare Holdings Limited
                14.2.10.1. Company Details
                14.2.10.2. Company Description
                14.2.10.3. Business Overview
                14.2.10.4. SWOT Analysis
                14.2.10.5. Strategic Overview

List of Tables

Table 01: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 03: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 07: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 08: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 09: U.S. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10: U.S. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 11: U.S. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 12: Canada Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 13: Canada Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 14: Canada Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 15: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, Drug Class, 2016–2026
Table 17: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 18: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 19: Germany Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 20: Germany Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 21: Germany Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 22: U.K. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: U.K. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 24: U.K. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 25: France Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 26: France Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 27: France Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 28: Italy Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 29: Italy Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 30: Italy Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 31: Spain Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 32: Spain Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 33: Spain Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 34: Rest of Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 35: Rest of Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 36: Rest of Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 37: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 38: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 39: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 40: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 41: China Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 42: China Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 43: China Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 44: Japan Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 45: Japan Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 46: Japan Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 47: India Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 48: India Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 49: India Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 50: Australia & New Zealand Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 51: Australia & New Zealand Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 52: Australia & New Zealand Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 53: Rest of Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 54: Rest of Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 55: Rest of Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 56: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 57: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 58: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 59: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 60: Brazil Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 61: Brazil Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 62: Brazil Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 63: Mexico Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 64: Mexico Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 65: Mexico Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 66: Rest of Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 67: Rest of Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 68: Rest of Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 69: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 70: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 71: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 72: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 73: GCC Countries Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 74: GCC Countries Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 75: GCC Countries Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 76: South Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 77: South Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 78: South Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 79: Israel Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 80: Israel Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 81: Israel Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 82: Rest of Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 83: Rest of Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 84: Rest of Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, 2016–2026
Figure 02: Global Thrombosis Drugs Y-o-Y Growth Rate (%), 2017–2026
Figure 03: Market Value Share, by Drug Class (2017)
Figure 04: Market Value Share, by Indication (2017)
Figure 05: Market Value Share, by Distribution Channel (2017)
Figure 07: Global Thrombosis Drugs Market, by Drug Product, 2017 and 2026
Figure 08: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor Xa Inhibitor, 2016–2026
Figure 09: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Low Molecular Weight Heparin, 2016–2026
Figure 10: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by P2Y12 Platelet Inhibitor, 2016–2026
Figure 11: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
Figure 12: Global Thrombosis Drugs Market Attractiveness, by Drug Class, 2018–2025
Figure 13: Global Thrombosis Drugs Market, by Indication, 2017 and 2026
Figure 14: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Pulmonary Embolism, 2016–2026
Figure 15: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Atrial Fibrillation, 2016–2026
Figure 16: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Deep Vein Thrombosis, 2016–2026
Figure 17: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Others, 2016–2026
Figure 18: Global Thrombosis Drugs Market Attractiveness, by Indication, 2018–2025
Figure 19: Global Thrombosis Drugs Market, by Distribution Channel, 2017 and 2026
Figure 20: Global Thrombosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Hospital Pharmacies, 2016–2026
Figure 21: Global Thrombosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Retail Pharmacies, 2016–2026
Figure 22: Global Thrombosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Online Pharmacies, 2016–2026
Figure 23: Global Thrombosis Drugs Market Attractiveness, by Distribution Channel, 2018–2025
Figure 24: Global Thrombosis Drugs Market Value Share, by Region, 2017 and 2026
Figure 25: Thrombosis Drugs Market Attractiveness Analysis, by Region, 2017–2026
Figure 26: North America Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 27: North America Thrombosis Drugs Market Value Share, by Country, 2017 and 2026
Figure 28: North America Thrombosis Drugs Market Attractiveness, by Country, 2017–2026
Figure 29: North America Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
Figure 30: North America Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
Figure 31: North America Thrombosis Drugs Market Value Share, by Indication, 2017 and 2026
Figure 32: North America Thrombosis Drugs Market Attractiveness, by Indication, 2017–2026
Figure 33: North America Thrombosis Drugs Market Value Share, by Distribution Channel, 2017 and 2026
Figure 34: North America Thrombosis Drugs Market Attractiveness, by Distribution Channel, 2017–2026
Figure 35: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 36: Europe Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 37: Europe Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 38: Europe Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
Figure 39: Europe Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
Figure 40: Europe Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
Figure 41: Europe Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
Figure 42: Europe Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
Figure 43: Europe Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026
Figure 44: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 45: Asia Pacific Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 46: Asia Pacific Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 47: Asia Pacific Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
Figure 48: Asia Pacific Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
Figure 49: Asia Pacific Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
Figure 50: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
Figure 51: Asia Pacific Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
Figure 52: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026
Figure 53: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 54: Latin America Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 55: Latin America Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 56: Latin America Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
Figure 57: Latin America Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
Figure 58: Latin America Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
Figure 59: Latin America Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
Figure 60: Latin America Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
Figure 61: Latin America Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026
Figure 62: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 63: Middle East & Africa Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 64: Middle East & Africa Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
Figure 65: Middle East & Africa Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
Figure 66: Middle East & Africa Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
Figure 67: Middle East & Africa Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
Figure 68: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
Figure 69: Middle East & Africa Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
Figure 70: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

155

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved